Janux Therapeutics, Inc. (JANX)
| Market Cap | 581.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.91M |
| Shares Out | 41.61M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,382 |
| Open | 14.45 |
| Previous Close | 14.27 |
| Day's Range | 13.78 - 14.96 |
| 52-Week Range | 13.79 - 37.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.00 (+150.4%) |
| Earnings Date | n/a |
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is 35.00, which is an increase of 150.36% from the latest price.
News
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics Reports Second Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today re...
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek...
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase...
LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...
Merck Partners With Newly Public Cancer Biotech
The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).
Janux Therapeutics stock opens at double the upsized IPO's pricing
Janux Therapeutics Inc. received a bullish reception on its Wall Street debut, as shares of the California-based biotechnology company developing cancer treatments opened at double the upsized initial p...